Abstract

With its 3,500-year history, aspirin is one of the most widely used medicines in the world. For a very long time, its place in secondary and sometimes even primary cardiovascular prevention was indisputable. However, a growing body of clinical data is calling this dogma into question. It is therefore necessary to reassess its efficacy and, above all, its safety in certain indications, such as primary cardiovascular prevention in at-risk populations, anti-platelet monotherapy following DES implantation, and post-acute coronary syndrome.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call